Articles

Find an Article

Filter articles

Applied Filters

Showing 301 to 310 of 319 results

Myriad: Keeping a low profile

US01-12-2012

The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

A step forward: new dosage patents in Mexico?

01-05-2012Pablo Fuentes

The status of patentability for new dosage regimes in Mexico is unclear, but there have been some positive signs, says Pablo Fuentes.

A question of fairness: preliminary injunctions in Mexico

01-05-2012Hedwig Lindner and Manuel Morante

The system governing preliminary injunctions for pharmaceutical patent infringement should be revised to stave off potential frivolous cases, say Hedwig Lindner and Manuel Morante.

Crossed wires: protecting medicines in Mexico

01-05-2012Daniel Sánchez and Victor Ramirez

When introducing medicinal products to any market, the strength of the trademark is crucial. But the Mexican system requires getting trademark approval from two different authorities.

Out in front: the Boston cluster

01-01-2012

When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne.

A new framework: challenging patents in changing times

01-01-2012Eldora Ellison and Eric Steffe

The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes.

Is there life for medical diagnostic patents after Prometheus?

01-01-2012MaryAnne Armstrong

The Supreme Court’s much-anticipated Prometheus decision has prompted strong reactions among IP practitioners, as MaryAnne Armstrong, PhD, explains.

Covering all the bases: An interview with BIO President Jim Greenwood

01-05-2011

BIO represents a broad constituency of biotechnology and life sciences companies. LSIPR talks to BIO president and CEO Jim Greenwood about patent reform, healthcare, court cases and plans for the future.

For better, for worse? How shifting IP laws change the global life sciences regulatory chessboard

01-05-2011

With IP laws around the world subject to frequent and sometimes unpredictable changes, it can be difficult to keep abreast of everything you need to know. Richard Gough and Jane Woodhouse take a look.

Building operative partnerships with law enforcement

01-05-2011Vaughn Volpi

There is a perfect storm brewing in the healthcare industry. Over the past few years, there has been an unprecedented rise in the trade of illicit healthcare products in the secondary market.

Showing 301 to 310 of 319 results

LSIPR